Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 5/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.37 |
| ▸ | DHODH | Q02127 | 3/20 | 0.37 |
| ▸ | PTPRB | P23467 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24518545 | 0.82 | CFTR (0.47) | SLC9A1KCNH2RBP4NOTUM | |
| SCHEMBL10148394 | 0.81 | NOTUM (0.40) | ASPHNOTUMKDM4C | |
| SCHEMBL18272375 | 0.75 | ACMSD (0.40) | ASPHNOTUM | |
| SCHEMBL12725573 | 0.73 | ASPH (0.46) | ASPHNOTUM | |
| SCHEMBL24518169 | 0.73 | SCN8A (0.41) | SLC9A1KCNH2KDM4C | |
| SCHEMBL24518542 | 0.73 | NOTUM (0.37) | SLC9A1KCNH2NOTUM | |
| SCHEMBL3829034 | 0.73 | NOTUM (0.37) | NOTUM | |
| SCHEMBL31188362 | 0.72 | SLC9A1 (0.50) | SLC9A1KCNH2RBP4CYP2C19CYP2D6 | |
| SCHEMBL664135 | 0.72 | SSTR5 (0.46) | RBP4CYP2C19CYP2D6NOTUM | |
| SCHEMBL3871135 | 0.71 | ASPH (0.47) | ASPHNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114437062-B | Compound capable of being used as sodium channel regulator and application thereof | 成都海博为药业有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4230618-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230618-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| CN-114031518-B | Benzylamine or benzyl alcohol derivative and application thereof | 成都海博为药业有限公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2022121517-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | 成都海博为药业有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022121517-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | 成都海博为药业有限公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-114437062-A | Compound capable of being used as sodium channel regulator and application thereof | 成都海博为药业有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-114031518-A | Benzylamine or benzyl alcohol derivative and application thereof | 成都海博为药业有限公司 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | SCN8A, SCN9A, SCN10A | SLC9A1 86/4885KCNH2 71/4885RBP4 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.